Category
Health Policy
Health policy decides who gets access to what, and on whose budget. Our coverage follows legislation, regulation and agency guidance across markets, with an emphasis on the decisions that move market access rather than the political theatre around them.
633 articles in this topic.
Articles in this category

11/18/2026
Ivonescimab Complete Response Letter: FDA Lists Four Reasons
The FDA complete response letter for ivonescimab (BLA 761524) cites China-heavy trial data, a modest PFS gain and the need for a new multiregional trial. Summit must resubmit or take another action within one year.
Read Article →
11/18/2026
FDA Launches Global Reliance Disclosure Program for Approval Packages
The FDA's Global Reliance Disclosure Program lets companies pass minimally redacted approval packages to regulators outside the US. Lenacapavir is the launch case, and the FDA intends to widen the program in January 2027. #SyenzaNews #MarketAccess
Read Article →
11/16/2026
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer
NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
11/13/2026
SADC Pharmaceutical Pooled Procurement Charter Signed in Durban
The Charter establishing the SADC Pharmaceuticals Pooled Procurement Services was signed in Durban on 12 November 2026, with Tanzania the first Member State to sign. #SyenzaNews #MarketAccess
Read Article →
11/12/2026
The EU HTA Regulation: What Latin America Can Learn
A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.
Read Article →
11/10/2026
Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up
Law 3563 creates a Neuquén health technology assessment agency. Guadalupe Montero explains how it will weigh safety, benefit, equity and budget impact.
Read Article →
11/10/2026
Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November
The Enzutrix patent dispute goes to South Africa's Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess
Read Article →
11/9/2026
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs
CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess
Read Article →
11/9/2026
Medicare drug price negotiation: CMS sets permanent rules
The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess
Read Article →
11/6/2026
Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit
The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.
Read Article →
11/4/2026
State AI Liability in Health Care: Lawsuits Test Insurers, Apps and Chatbots
A Congressional Research Service sidebar maps the state lawsuits over AI in health care, from insurer claim denials to wellness apps and chatbots.
Read Article →
11/4/2026
EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment
The EMA mid-year report 2026 records 485 scientific advice requests in the first half, the first joint clinical assessment under the HTA Regulation and progress on the new pharmaceutical law. #SyenzaNews #MarketAccess
Read Article →


